By using, you agree to our terms and use of cookies to enhance your experience.

First oral GLP-1 results unveiled

By Editor
21st April 2016
Latest news, Pharmaceutical Research

The first oral glucagon-like peptide 1 receptor agonist (GLP-1) has shown promising results in treating type 2 diabetes.

Data revealed at the Keystone Symposia on New Therapeutics for Diabetes and Obesity demonstrated that TPP273, a new oral small molecule form of a GLP-1 receptor agonist, may have several benefits over current IV formulations, including predictably lowering blood glucose levels without side effects such as nausea and vomiting.

TTP273 was also shown to be safe, and based on the data presented, significant decreases in HbA1c and body weight are expected in the ongoing Phase 2 study.

Side effects

The research is being carried out by clinical-stage biopharmaceutical company vTv Therapeutics Inc.

Dr. Carmen Valcarce, Chief Scientific Officer from the company, said: “GLP-1 receptor agonists are well-validated treatments that provide glycemic control and weight loss for type 2 diabetes patients.

“But their limitations—including side effects like nausea and vomiting, and the fact that current products are available only as an injection—have reduced their potential to help many more patients.

We believe an orally dosed GLP-1R agonist with significantly reduced rates of nausea and vomiting would bring a truly differentiated product to this substantial market. We’re looking forward to revealing results of the ongoing Phase 2 clinical trial at the end of 2016.”

Superior safety

Also at the conference, a poster was presented related to TTP399, the company’s Glucokinase Activator (GKA), which is currently in a Phase 2b trial for the treatment of type 2 diabetes.

In a poster titled, ‘The Importance of Tissue Selectivity and Preservation of the Physiological Regulation when Targeting Key Metabolic Regulators as Glucokinase,” vTv scientists presented evidence of TTP399’s liver selectivity.

Targeting liver cells is key to the compound’s ability to normalise blood glucose without inducing hypoglycemia, dyslipidemia or other toxicities.

The data suggests TTP399 may have a superior safety and efficacy profile over previously studied GKA compounds.

Data from a controlled Phase 2b trial of TTP399 in type 2 diabetes patients is expected in the summer of 2016.

Comments (0)

Register an account or login to comment